Context Therapeutics
CNTX
43 hedge funds and large institutions have $96M invested in Context Therapeutics in 2025 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 4 closing their positions.
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
44% more capital invested
Capital invested by funds: $66.8M → $96M (+$29.2M)
16% more funds holding
Funds holding: 37 → 43 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
5.81% less ownership
Funds ownership: 76.88% → 71.07% (-5.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$3.04M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$2.99M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$340K |
| 4 |
Renaissance Technologies
New York
|
+$220K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$106K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$4.7M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$4.06M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.9M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
-$390K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$80.6K |
CNTX Hedge Fund Activity: Q4 2025 in Review
43 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in Context Therapeutics (CNTX) for Q4 2025, worth a combined $96M — up 44% from $66.8M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CNTX positions and 4 closed out — a net gain of 6 holders — while 8 added to existing stakes and 8 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $3.04M. The largest seller was MPM BioImpact, cutting an estimated $4.7M.
- 43 institutional investors held Context Therapeutics (CNTX) as of Q4 2025, up from 37 in Q3 2025.
- Funds reported $96M of Context Therapeutics stock for Q4 2025, up 44% quarter-over-quarter.
- 10 funds opened new Context Therapeutics positions in Q4 2025 and 4 closed out, a net change of +6 holders.
- The largest Context Therapeutics buyer in Q4 2025 was Millennium Management, an estimated $3.04M added.
- The largest Context Therapeutics seller in Q4 2025 was MPM BioImpact, an estimated $4.7M sold.
Based on aggregated 13F filings for Q4 2025.